Literature DB >> 12036806

Abnormal lipid concentrations in cystic fibrosis.

Veronica Figueroa1, Carlos Milla, Elizabeth J Parks, Sarah Jane Schwarzenberg, Antoinette Moran.   

Abstract

BACKGROUND: Concentrations of cholesterol and triacylglycerol are commonly believed to be low in persons with cystic fibrosis and thus not of concern.
OBJECTIVE: The goal was to determine whether concentrations of cholesterol and triacylglycerol are related to glucose tolerance or nutritional status in patients with cystic fibrosis.
DESIGN: Fasting lipid profiles were measured in 192 patients ( +/- SD age: 21 +/- 11 y) in conjunction with an oral-glucose-tolerance test.
RESULTS: Cystic fibrosis patients in all age groups had higher triacylglycerol (1.51 +/- 0.95 mmol/L) and lower cholesterol (3.57 +/- 0.96 mmol/L) concentrations than US population means. Thirty patients (16%) had hypertriglyceridemia (3.22 +/- 1.22 mmol/L), and 8 patients (4%) had elevated cholesterol (6.05 +/- 1.32 mmol/L). In most cases, hypertriglyceridemia was isolated; only 3 subjects had elevation of both cholesterol and triacylglycerol. Lipid concentrations were not related to body mass index, weight, glucose tolerance, the areas under the curve for glucose or insulin, or glycated hemoglobin. Lipid concentrations also did not correlate with cystic fibrosis genotype, use of systemic steroids, blood pressure, liver enzymes, C-reactive protein, or pulmonary function.
CONCLUSIONS: Isolated hypertriglyceridemia appears to be common in cystic fibrosis, whereas cholesterol concentrations are generally low. Hypertriglyceridemia may be related to chronic low-grade inflammation or to a dietary macronutrient imbalance with excessive simple carbohydrate absorption relative to fat absorption. Whether it is associated with a risk of cardiovascular disease in this population is uncertain, but the clinical significance of triacylglycerol elevation may become important as survival improves.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036806     DOI: 10.1093/ajcn/75.6.1005

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  24 in total

1.  Ischaemic heart disease--a new issue in cystic fibrosis?

Authors:  Felicity M R Perrin; Walter Serino
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

2.  A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF-Inhibitor Mediated Attenuation of Bleomycin-Induced Pulmonary Fibrosis.

Authors:  Yogesh M Kulkarni; Sucharita Dutta; Anand Krishnan V Iyer; Clayton A Wright; Vani Ramesh; Vivek Kaushik; Oliver John Semmes; Neelam Azad
Journal:  Proteomics Clin Appl       Date:  2018-01-19       Impact factor: 3.494

3.  Proof of concept for identifying cystic fibrosis from perspiration samples.

Authors:  Zhenpeng Zhou; Daniel Alvarez; Carlos Milla; Richard N Zare
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-18       Impact factor: 11.205

4.  Metabolic Profiling of Human Blood by High Resolution Ion Mobility Mass Spectrometry (IM-MS).

Authors:  Prabha Dwivedi; Albert J Schultz; Herbert H Hill
Journal:  Int J Mass Spectrom       Date:  2010-12       Impact factor: 1.986

5.  Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry.

Authors:  Todd MacKenzie; Alex H Gifford; Kathryn A Sabadosa; Hebe B Quinton; Emily A Knapp; Christopher H Goss; Bruce C Marshall
Journal:  Ann Intern Med       Date:  2014-08-19       Impact factor: 25.391

6.  Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients.

Authors:  Mario Ollero; Giuseppe Astarita; Ida Chiara Guerrera; Isabelle Sermet-Gaudelus; Stéphanie Trudel; Daniele Piomelli; Aleksander Edelman
Journal:  J Lipid Res       Date:  2011-02-18       Impact factor: 5.922

7.  CFTR depletion results in changes in fatty acid composition and promotes lipogenesis in intestinal Caco 2/15 cells.

Authors:  Geneviève Mailhot; Rémi Rabasa-Lhoret; Alain Moreau; Yves Berthiaume; Emile Levy
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

Review 8.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

9.  Alteration of Membrane Cholesterol Content Plays a Key Role in Regulation of Cystic Fibrosis Transmembrane Conductance Regulator Channel Activity.

Authors:  Guiying Cui; Kirsten A Cottrill; Kerry M Strickland; Sarah A Mashburn; Michael Koval; Nael A McCarty
Journal:  Front Physiol       Date:  2021-06-07       Impact factor: 4.566

10.  Dyslipidemia in racially admixtured children with cystic fibrosis.

Authors:  Cresio Alves; Daniela Lima; Mauricio Cardeal; Angelica Santana
Journal:  Indian J Endocrinol Metab       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.